Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03294694
Title Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

peritoneum cancer

Her2-receptor negative breast cancer

ovarian cancer

fallopian tube cancer


Fulvestrant + Ribociclib + Spartalizumab

Ribociclib + Spartalizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.